Targeting lysine methylation for latency reversal in HIV-infected drug users
Targeting lysine methylation for latency reversal in HIV-infected drug users
批准号:
9236043
负责人:
Melanie Maria Ott
金额:
$59.84万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2021-06-30
关键词:
AIDS/HIV problemATAC-seqAcquired Immunodeficiency SyndromeAddressAffectAmphetaminesAutopsyBindingBiological AssayBrainCD4 Positive T LymphocytesCRISPR/Cas technologyCellsChromatinChronicClinicalCocaineCocaine UsersDevelopmentDrug TargetingDrug usageDrug userEnzymesEpigenetic ProcessFailureFundingFutureGenesGenetic TranscriptionGoalsHIVHIV therapyHistone AcetylationHistone H3Histone H4HistonesIndividualInfectionKnowledgeLaboratoriesLeadLinkLysineMalignant NeoplasmsMapsMass Spectrum AnalysisMeasuresMethamphetamineMethylationMethyltransferaseMicroarray AnalysisMidbrain structureMissionModificationMusPharmaceutical PreparationsPharmacologic SubstancePlayPost-Translational Protein ProcessingProtein AcetylationProtein MethylationProteinsProvirusesPublic HealthPublishingRegulationResearchResearch SupportRoleSubstance abuse problemTechnologyTestingTherapeuticTranscription Repressor/CorepressorTranscriptional RegulationTransposaseViralWorkbasechromatin immunoprecipitationclinical applicationcocaine exposurecocaine useepigenetic drugepigenetic regulationepigenomicsgene repressionhistone methylationimprovedin vivoinhibitor/antagonistinnovationinterestneglectpersonalized approachpre-clinicalpromoterresearch studyresponsesmall moleculesmall molecule inhibitortargeted treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT ABSTRACT
Stimulant drugs induce wide-spread epigenetic perturbations in the brain, but their effects on the epigenetic
regulation of the latent HIV provirus and responses to latency-reversing therapies targeting this regulation are
unknown. The central hypothesis of this application is that histone methylation by the SET and MYND domain-
containing enzyme Smyd2 (also called KMT3C) is a robust latency-inducing mechanism and a new target for
latency-reversing therapy in HIV+ cocaine users. This hypothesis was formulated on the basis of preliminary
results generated by the applicant identifying Smyd2, among 45 cellular lysine methyltransferases, as a top
enzyme that suppresses HIV transcription in latent CD4+ T cells. It is also based on published work by others
showing that expression of G9a, another methyltransferase linked to HIV latency, is decreased in the brain
after chronic cocaine exposure, while expression of Smyd2 is unchanged. The central hypothesis will be tested
in three specific aims: 1) Define how Smyd2 functions as transcriptional repressor in HIV latency. The working
hypothesis is that Smyd2, by associating with the latent-HIV promoter in vivo, induces durable transcriptional
repression despite cocaine exposure. The applicant will test this hypothesis with CRISPR/Cas9 gene–editing
technology and by examining the mode of Smyd2 recruitment with and without cocaine exposure. She will also
test latency reversal in response to small-molecule Smyd2 inhibitors in CD4+ T cells isolated from HIV+ cocaine
users. 2) Determine the lysine methylation mark(s) set by Smyd2 at the latent HIV promoter. The working
hypothesis is that monomethylation of lysine 20 at histone H4 (H4K20me1) is the main mark set by Smyd2 at
the latent viral promoter during cocaine exposure. The applicant will test this hypothesis by determining the
methyl marks introduced by Smyd2 using mass spectrometry and by performing chromatin
immunoprecipitations (ChIP) for Smyd2 histone–methyl marks in latent cells with and without cocaine
treatment. 3) Identify the mechanism underlying how H4K20me1 induces HIV latency. The working hypothesis
is that H4K20me1 at the latent provirus is bound by the MBT-containing protein L3MBTL1, which induces
chromatin compaction and, thus, durable transcriptional repression and latency with cocaine exposure. The
applicant will test this hypothesis by performing ChIP and histone accessibility assays (ATAC-Seq) to measure
L3MBTL1 recruitment and chromatin compaction, respectively, in latent cells with and without cocaine
exposure. Successful completion of this proposal will significantly enhance the understanding of epigenomic
regulatory mechanisms in HIV/AIDS infection in combination with substance abuse in alignment with this RFA.
The proposed research is innovative because it represents a new and substantive departure from the status
quo by shifting the focus in HIV latency research to monomethylation of histone H4, recruitment of L3MBTL1,
and induction of histone compaction. Based on this work, the applicant expects to make important advances in
therapies for HIV+ drug users and in improving the understanding of the epigenetics of drug use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In vitro virology core
-
批准号:10512624
-
项目类别:
-
资助金额:$743.75万
-
财政年份:2022
-
负责人:Melanie Maria Ott
-
依托单位:
Modeling intestinal dysfunction in HIV infection with organoid technology
-
批准号:10542390
-
项目类别:
-
资助金额:$78.98万
-
财政年份:2020
-
负责人:Melanie Maria Ott
-
依托单位:
Modeling intestinal dysfunction in HIV infection with organoid technology
-
批准号:9894660
-
项目类别:
-
资助金额:$81.11万
-
财政年份:2020
-
负责人:Melanie Maria Ott
-
依托单位:
Modeling intestinal dysfunction in HIV infection with organoid technology
-
批准号:10083740
-
项目类别:
-
资助金额:$78.98万
-
财政年份:2020
-
负责人:Melanie Maria Ott
-
依托单位:
Modeling intestinal dysfunction in HIV infection with organoid technology
-
批准号:10322720
-
项目类别:
-
资助金额:$78.98万
-
财政年份:2020
-
负责人:Melanie Maria Ott
-
依托单位:
Exploring HIV-associated Neurocognitive Disorder (HAND) and HIV Latency at the Single Cell Level in Cerebral Organoids
-
批准号:10466829
-
项目类别:
-
资助金额:$70.8万
-
财政年份:2019
-
负责人:Melanie Maria Ott
-
依托单位:
Single-Cell Transcriptomics of Non-Activated Latently Infected T cells Isolated from HIV+ Drug Users
-
批准号:10548752
-
项目类别:
-
资助金额:$94.18万
-
财政年份:2019
-
负责人:Melanie Maria Ott
-
依托单位:
Harnessing the RNA-Binding Properties of Cas13a for HIV-1 Self-Testing
-
批准号:10423661
-
项目类别:
-
资助金额:$88.45万
-
财政年份:2019
-
负责人:Melanie Maria Ott
-
依托单位:
Harnessing the RNA-Binding Properties of Cas13a for HIV-1 Self-Testing
-
批准号:10456229
-
项目类别:
-
资助金额:$88.94万
-
财政年份:2019
-
负责人:Melanie Maria Ott
-
依托单位:
Exploring HIV-associated Neurocognitive Disorder (HAND) and HIV Latency at the Single Cell Level in Cerebral Organoids
-
批准号:10678898
-
项目类别:
-
资助金额:$70.8万
-
财政年份:2019
-
负责人:Melanie Maria Ott
-
依托单位:
PROJECT 2: Determine clinically relevant host-viral dependency networks for respiratory infections including SARS-CoV-2
-
批准号:10550002
-
项目类别:
-
资助金额:$67.25万
-
财政年份:2018
-
负责人:Melanie Maria Ott
-
依托单位:
Harnessing the RNA-Binding Properties of Cas13a for HIV-1 Self-Testing
-
批准号:9750303
-
项目类别:
-
资助金额:$46.86万
-
财政年份:2018
-
负责人:Melanie Maria Ott
-
依托单位:
Harnessing the RNA-Binding Properties of Cas13a for HIV-1 Self-Testing
-
批准号:9982198
-
项目类别:
-
资助金额:$47.88万
-
财政年份:2018
-
负责人:Melanie Maria Ott
-
依托单位:
Assessing the root causes of chronic inflammation in HIV-infected individuals using drugs of abuse
-
批准号:10155457
-
项目类别:
-
资助金额:$71.45万
-
财政年份:2017
-
负责人:Melanie Maria Ott
-
依托单位:
Role of Lipid Droplets in Hepatitis C Virus Infection
-
批准号:8728531
-
项目类别:
-
资助金额:$47.75万
-
财政年份:2014
-
负责人:Melanie Maria Ott
-
依托单位:
A new model of accelerated immune aging in HIV-infected drug users
-
批准号:8763847
-
项目类别:
-
资助金额:$95.5万
-
财政年份:2014
-
负责人:Melanie Maria Ott
-
依托单位:
Role of Lipid Droplets in Hepatitis C Virus Infection
-
批准号:9040083
-
项目类别:
-
资助金额:$47.75万
-
财政年份:2014
-
负责人:Melanie Maria Ott
-
依托单位:
Promoting Underrepresented Minority Advancement in the Sciences (PUMAS)
-
批准号:8616676
-
项目类别:
-
资助金额:$3.15万
-
财政年份:2014
-
负责人:Melanie Maria Ott
-
依托单位:
Promoting Underrepresented Minority Advancement in the Sciences (PUMAS)
-
批准号:9041012
-
项目类别:
-
资助金额:$5.88万
-
财政年份:2014
-
负责人:Melanie Maria Ott
-
依托单位:
Role of Lipid Droplets in Hepatitis C Virus Infection
-
批准号:9265409
-
项目类别:
-
资助金额:$47.75万
-
财政年份:2014
-
负责人:Melanie Maria Ott
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:柳静
-
依托单位:
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
-
批准号:62302218
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:张双全
-
依托单位:
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:黄铭坤
-
依托单位:
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
-
批准号:32100438
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:涂晓雨
-
依托单位:
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
-
批准号:82001520
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:汤小晗
-
依托单位:
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
-
批准号:81802809
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:蔡梅春
-
依托单位:
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
-
批准号:31802046
-
项目类别:青年科学基金项目
-
资助金额:27.0万元
-
批准年份:2018
-
负责人:张龚炜
-
依托单位:
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
-
批准号:31801915
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2018
-
负责人:茹磊
-
依托单位:
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
-
批准号:31871331
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:张治华
-
依托单位: